Citations 1
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.
Molina, Julian R. , Kim, Joo-Hang , Arvis, Catherine Dubos, Ahn, Myung‐Ju , Fidler, Mary J. , Gubens, Matthew A. , Castro, Gilberto de , Shentu, Yue , Im, Ellie, Lubiniecki, Gregory M., Baas, Paul, Garon, Edward B. , Herbst, Roy S. , Kim, Dong‐Wan , Felip, Enriqueta , Perez‐Gracia, José Luis , Han, Ji-Youn , Majem, Margarita , Garrido, Marcelo , Baas, Paul
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9024-9024
